351333-74-9

Upstream product

• 17282-38-1 1-(4-methylphenacyl)pyridinium bromide 
• 586-89-0 4-acetyl-benzoic acid 

Downstream Products

• 351333-87-4 N-(6-amino-hexyl)-4-{6-[4-(2-dimethylamino-ethylsulfanylmethyl)-phenyl]-pyridin-2-yl}-benzamide 
• 351333-86-3 N-(4-amino-butyl)-4-{6-[4-(2-dimethylamino-ethylsulfanylmethyl)-phenyl]-pyridin-2-yl}-benzamide 
• 351333-76-1 4-(2-[6-(4-[2-(dimethylamino)ethyl]thiomethyl)-phenyl]pyridyl)benzoate 
• 351333-85-2 4-[6-(4-bromomethyl-phenyl)-pyridin-2-yl]-benzoic acid ethyl ester 
• 287099-70-1 N-(2-aminoethyl)-4-(6-[4-{(2-dimethylaminoethyl)thiomethyl}-phenyl]pyridin-2-yl)benzamide 
• 351333-75-0 ethyl 4-(2-[6-(4-tolyl)pyridyl])benzoate 

Relevant academic research and scientific papers

COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE

The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.